MX2021007548A - Adc con enlazadores multiplex de tiol. - Google Patents
Adc con enlazadores multiplex de tiol.Info
- Publication number
- MX2021007548A MX2021007548A MX2021007548A MX2021007548A MX2021007548A MX 2021007548 A MX2021007548 A MX 2021007548A MX 2021007548 A MX2021007548 A MX 2021007548A MX 2021007548 A MX2021007548 A MX 2021007548A MX 2021007548 A MX2021007548 A MX 2021007548A
- Authority
- MX
- Mexico
- Prior art keywords
- adcs
- thiol
- multiplex
- linkers
- mlas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783582P | 2018-12-21 | 2018-12-21 | |
| US201862783707P | 2018-12-21 | 2018-12-21 | |
| PCT/US2019/068178 WO2020132655A1 (en) | 2018-12-21 | 2019-12-20 | Adcs with thiol multiplex linkers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021007548A true MX2021007548A (es) | 2021-12-10 |
Family
ID=71101991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021007548A MX2021007548A (es) | 2018-12-21 | 2019-12-20 | Adc con enlazadores multiplex de tiol. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220040320A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3897734A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022514348A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210141918A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113543812A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019403552A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3122316A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL284147A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021007548A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202106122QA (cg-RX-API-DMAC7.html) |
| TW (1) | TW202039008A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020132655A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021251875A1 (en) * | 2020-04-10 | 2022-11-03 | Seagen Inc. | Charge variant linkers |
| IL317037A (en) * | 2022-05-18 | 2025-01-01 | Systimmune Inc | Ligand-drug conjugate and its uses |
| EP4651905A1 (en) * | 2023-01-17 | 2025-11-26 | Eli Lilly and Company | Novel linkers for sustained delivery of therapeutics |
| LT4601703T (lt) | 2023-04-18 | 2026-06-25 | Astrazeneca Ab | Konjugatai, apimantys atskeliamuosius jungtukus |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0871490B1 (en) * | 1995-12-22 | 2003-03-19 | Bristol-Myers Squibb Company | Branched hydrazone linkers |
| EP0941120A4 (en) * | 1996-11-05 | 2004-08-18 | Bristol Myers Squibb Co | BRANCHED PEPTIDLINKERS |
| DE10048417A1 (de) * | 2000-09-29 | 2002-04-11 | Roche Diagnostics Gmbh | Verbindungen mit verzweigtem Linker |
| US6821529B2 (en) * | 2001-09-05 | 2004-11-23 | Deanna Jean Nelson | Oligo(ethylene glycoll)-terminated 1,2-dithiolanes and their conjugates useful for preparing self-assembled monolayers |
| WO2007132998A1 (en) * | 2006-05-12 | 2007-11-22 | Korea Research Institute Of Bioscience And Biotechnology | Linker molecules for substrate surface treatment and specific protein immobilization, and method for preparing the same |
| WO2012024613A1 (en) * | 2010-08-19 | 2012-02-23 | Wintrance Corporation | Synergistic biomolecule-polymer conjugates |
| WO2008147481A1 (en) * | 2007-02-09 | 2008-12-04 | Northeastern University | Precision-guided nanoparticle systems for drug delivery |
| EP3842074A1 (en) * | 2010-09-29 | 2021-06-30 | Philogen S.p.A. | Protein-drug conjugates |
| CN104822656B (zh) * | 2012-05-15 | 2018-05-01 | 西雅图基因公司 | 自稳定接头偶联物 |
| CN104640572B (zh) * | 2012-05-15 | 2018-04-27 | 索伦托医疗有限公司 | 药物偶联物,偶联方法,及其用途 |
| PL2872157T3 (pl) * | 2012-07-12 | 2020-07-13 | Hangzhou Dac Biotech Co., Ltd | Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi |
| JP2016531915A (ja) * | 2013-08-28 | 2016-10-13 | ステムセントリックス, インコーポレイテッド | 部位特異的抗体コンジュゲーション方法および組成物 |
| TW201511774A (zh) * | 2013-09-18 | 2015-04-01 | Iner Aec Executive Yuan | 放射性標誌之主動標靶性醫藥組合物及其用途 |
| PT3057585T (pt) * | 2013-10-15 | 2020-10-21 | Seagen Inc | Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando |
| WO2016025752A1 (en) * | 2014-08-14 | 2016-02-18 | Prolynx Llc | Reagents for thiol conjugation and conjugates formed therefrom |
| US11135307B2 (en) * | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
| AU2021251875A1 (en) * | 2020-04-10 | 2022-11-03 | Seagen Inc. | Charge variant linkers |
-
2019
- 2019-12-20 AU AU2019403552A patent/AU2019403552A1/en not_active Abandoned
- 2019-12-20 KR KR1020217022058A patent/KR20210141918A/ko not_active Abandoned
- 2019-12-20 JP JP2021535547A patent/JP2022514348A/ja not_active Ceased
- 2019-12-20 WO PCT/US2019/068178 patent/WO2020132655A1/en not_active Ceased
- 2019-12-20 CN CN201980085333.XA patent/CN113543812A/zh active Pending
- 2019-12-20 MX MX2021007548A patent/MX2021007548A/es unknown
- 2019-12-20 CA CA3122316A patent/CA3122316A1/en active Pending
- 2019-12-20 EP EP19900437.5A patent/EP3897734A4/en not_active Withdrawn
- 2019-12-20 SG SG11202106122QA patent/SG11202106122QA/en unknown
- 2019-12-20 US US17/311,508 patent/US20220040320A1/en not_active Abandoned
- 2019-12-23 TW TW108147276A patent/TW202039008A/zh unknown
-
2021
- 2021-06-17 IL IL284147A patent/IL284147A/en unknown
-
2024
- 2024-09-20 JP JP2024163811A patent/JP2024178320A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019403552A1 (en) | 2021-06-17 |
| CN113543812A (zh) | 2021-10-22 |
| TW202039008A (zh) | 2020-11-01 |
| JP2022514348A (ja) | 2022-02-10 |
| EP3897734A1 (en) | 2021-10-27 |
| WO2020132655A1 (en) | 2020-06-25 |
| KR20210141918A (ko) | 2021-11-23 |
| US20220040320A1 (en) | 2022-02-10 |
| EP3897734A4 (en) | 2022-12-07 |
| IL284147A (en) | 2021-08-31 |
| SG11202106122QA (en) | 2021-07-29 |
| CA3122316A1 (en) | 2020-06-25 |
| JP2024178320A (ja) | 2024-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202102353B (en) | Conjugation linkers containing 2,3-diaminosuccinyl group | |
| MX2024014691A (es) | Enlazadores de conjugacion mejorados | |
| MY206244A (en) | Anti-muc1 antibody-drug conjugate | |
| MX2020002666A (es) | Conjugados de anticuerpos anti-receptor de folato, composiciones que contienen conjugados de anticuerpos anti-receptor de folato y metodos de fabricación y uso de conjugados de anticuerpos anti-receptor de folato. | |
| CL2021001790A1 (es) | Enlazadores sin trazas, conjugados de proteínas de los mismos y composiciones de los mismos | |
| WO2020236841A3 (en) | Antibody drug conjugates having linkers comprising hydrophilic groups | |
| CL2011000835A1 (es) | Compuestos derivados de espiro-oxindol; moduladores de los canales de sodio; composicion farmaceutica que comprende a dicho compuesto; y uso en el tratamiento del dolor, depresion, enfermedades cardiovasculares, respiratorias, psiquiatricas, entre otras. | |
| HN2006019066A (es) | "(s)-n-metilnaltrexona" | |
| EP1747265A4 (en) | Multi-lineage progenitor cells | |
| CL2008000669A1 (es) | Compuestos derivados de tiazolidindionas n alquiladas, moduladores del receptor alfa relacionados con estrogenos; composicion farmaceutica; y su uso para tratar enfermedades relacionadas con los huesos, cancer, sindrome metabolicos, entre otras. | |
| CL2023003604A1 (es) | Conjugados de neodegradadores | |
| UY30304A1 (es) | Moduladores de mglur5 i | |
| ECSP099574A (es) | Agonistas adrenoreceptores alfa2c | |
| UY30308A1 (es) | Moduladores de mglur5 v | |
| CL2018002050A1 (es) | Conjugados anticuerpo-fármaco dirigidos a gcc. | |
| GT200800107A (es) | Formulaciones orales que comprenden tigeciclina | |
| MX2010001955A (es) | Enlazadores polimericos que contienen porciones de disulfuro-piridilo. | |
| GT199800028S (es) | Diseño de tableta. | |
| PH12020551502A1 (en) | Viewing optic with a base having a light module | |
| ZA202211405B (en) | Anti-cd73-anti-pd-1 bispecific antibody and use thereof | |
| UY30306A1 (es) | Moduladores de mglur5 iii | |
| ECSP21089206A (es) | Conjugados de anticuerpo y fármaco | |
| MX2024014070A (es) | Composicion farmaceutica que contiene un conjugado de anticuerpo anti-nectina-4 y uso del mismo | |
| UY30307A1 (es) | Moduladores de mglur5 vi | |
| CO2025003362A2 (es) | Conjugados de fármacos anticuerpo anti-sez6 |